StoxZydus Lifesciences vs Aurobindo Pharma: share price & financials comparison
NSE: ZYDUSLIFE vs AUROPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Zydus Lifesciences vs Aurobindo Pharma at a glance
Zydus Lifesciences (ZYDUSLIFE) has a market capitalisation of ₹1,18,752 Cr, against ₹1,04,907 Cr for Aurobindo Pharma (AUROPHARMA). Over the past year Aurobindo Pharma has returned +58.7%, compared with +22.5% for Zydus Lifesciences. On valuation, Aurobindo Pharma trades at a lower P/E of 26.3 versus 28.4. Zydus Lifesciences earns a higher return on equity (15.0% vs 10.1%). Zydus Lifesciences comes out ahead on size, profitability and growth. Aurobindo Pharma comes out ahead on valuation, financial health, momentum and technicals. Across the scored metrics below, Zydus Lifesciences leads on 9 and Aurobindo Pharma on 9. On StoxGud's 10-point checklist, Zydus Lifesciences scores 10/10 and Aurobindo Pharma scores 8/10.
| Metric | Zydus Lifesciences | Aurobindo Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,18,752 Cr | ₹1,04,907 Cr |
| Revenue (latest FY) | ₹27,148 Cr | ₹33,653 Cr |
| Net profit (latest FY) | ₹5,040 Cr | ₹3,505 Cr |
| Valuation | ||
| P/E | 28.4 | 26.3 |
| P/B | 4.27 | 2.66 |
| Dividend yield | 0.93% | 0.22% |
| Profitability | ||
| Return on equity | 15.0% | 10.1% |
| Net profit margin | 13.8% | 10.8% |
| Operating margin | 27.0% | 20.5% |
| Growth | ||
| Revenue growth (YoY) | +29.2% | +23.9% |
| Net profit growth (YoY) | -26.5% | +32.7% |
| Revenue CAGR (multi-year) | +12.4% | +6.3% |
| Financial health | ||
| Debt to equity | 0.48 | 0.21 |
| Momentum | ||
| 1-month return | +5.1% | +8.2% |
| 1-year return | +22.5% | +58.7% |
| 3-year CAGR | +24.2% | +23.0% |
| 5-year CAGR | +19.3% | +21.3% |
| 10-year CAGR | +12.8% | +9.5% |
| Distance from 52W high | -4.5% | -1.7% |
| Technicals | ||
| RSI (14) | 63 | 86 |
| Price vs 200-day avg | +13.6% | +22.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Zydus Lifesciences | Aurobindo Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 10/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Zydus Lifesciences or Aurobindo Pharma?
Zydus Lifesciences has a market cap of ₹1,18,752 Cr and Aurobindo Pharma has a market cap of ₹1,04,907 Cr as of 13 Nov 2026.
Which has a lower P/E, Zydus Lifesciences or Aurobindo Pharma?
Aurobindo Pharma has the lower P/E: Zydus Lifesciences trades at 28.4 and Aurobindo Pharma at 26.3.
Which gave better returns in the last year, Zydus Lifesciences or Aurobindo Pharma?
Aurobindo Pharma did better: Zydus Lifesciences returned +22.5% and Aurobindo Pharma returned +58.7% over one year.
What is the difference between Zydus Lifesciences and Aurobindo Pharma?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹1,18,752 Cr vs ₹1,04,907 Cr). In the latest financial year Zydus Lifesciences reported revenue of ₹27,148 Cr and Aurobindo Pharma ₹33,653 Cr. Operating margin is 27.0% for Zydus Lifesciences and 20.5% for Aurobindo Pharma. Debt to equity is 0.48 for Zydus Lifesciences and 0.21 for Aurobindo Pharma.
Which is better, Zydus Lifesciences or Aurobindo Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Zydus Lifesciences leads on 9 and Aurobindo Pharma on 9. Zydus Lifesciences is ahead on size, profitability and growth. Aurobindo Pharma is ahead on valuation, financial health, momentum and technicals. On StoxGud's rules-based checklist Zydus Lifesciences scores 10/10 and Aurobindo Pharma scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.